European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast, adverse events (AEs) are often reported as infrequent, minor, tolerable and manageable, but they are increasingly important...

Descripción completa

Detalles Bibliográficos
Autores principales: Steegmann, J L, Baccarani, M, Breccia, M, Casado, L F, García-Gutiérrez, V, Hochhaus, A, Kim, D-W, Kim, T D, Khoury, H J, Le Coutre, P, Mayer, J, Milojkovic, D, Porkka, K, Rea, D, Rosti, G, Saussele, S, Hehlmann, R, Clark, R E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991363/
https://www.ncbi.nlm.nih.gov/pubmed/27121688
http://dx.doi.org/10.1038/leu.2016.104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991363/
https://www.ncbi.nlm.nih.gov/pubmed/27121688
http://dx.doi.org/10.1038/leu.2016.104

Ejemplares similares